DNMT3A and cardiac hypertrophy: Specifically, DNMT3A−/− engineered human induced pluripotent stem cell-derived cardiomyocytes have up-regulation of pathways involved in cardiac hypertrophy and cardiac proliferation pathways when compared with WT [108].